Skip Navigation


Brain Advance Access originally published online on April 19, 2007
Brain 2007 130(5):1235-1243; doi:10.1093/brain/awm062
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
130/5/1235    most recent
awm062v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Takahashi, T.
Right arrow Articles by Itoyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, T.
Right arrow Articles by Itoyama, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial use License (http://creativecommons.org/lisences/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distributed, and reproduction in medium, provided the original work is properly cited.

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre

Toshiyuki Takahashi1, Kazuo Fujihara1, Ichiro Nakashima1, Tatsuro Misu1, Isabelle Miyazawa1, Masashi Nakamura1, Shohei Watanabe1, Yusei Shiga1, Chihiro Kanaoka2, Juichi Fujimori3, Shigeru Sato3 and Yasuto Itoyama1

1Department of Neurology, Tohoku University Graduate School of Medicine, 2Department of Neurology, Tohoku Welfare Pension Hospital and 3Department of Neurology, Konan Hospital, Sendai, Japan

Correspondence to: Toshiyuki Takahashi, MD, Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aobaku, Sendai 980-8574, Japan E-mail: toshiyuki{at}em.neurol.med.tohoku.ac.jp

NMO-IgG is a disease-specific autoantibody for neuromyelitis optica (NMO) and its target antigen is aquaporin-4 (AQP4) water channel. Recently, we established a sensitive anti-AQP4 antibody assay using human AQP4-transfected cells, which appeared more sensitive than the original NMO-IgG assay. So far, there has been no large-scale study on anti-AQP4 antibody titre in NMO and related disorders. We tested 148 sera of patients with NMO, high-risk syndrome of NMO, multiple sclerosis (MS), clinically isolated syndrome suggestive of MS and miscellaneous diseases. We analysed the relation of anti-AQP4 antibody titres and clinical and laboratory parameters. The sensitivity of anti-AQP4 antibody assay was 91% (95% CI 79–100) for NMO and 85% (65–100) for high-risk syndrome, and the specificity was 100% (91–100) for NMO and high-risk syndrome, that is, none with the other disorders was positive. Among 21 anti-AQP4 antibody-positive cases whose NMO-IgG were tested, 15 were NMO-IgG-positive and 6 were NMO-IgG-negative. Higher anti-AQP4 antibody titres were associated with complete blindness and extensive or large cerebral lesions on MRI. The lengths of spinal cord lesions on MRI were positively correlated with the titres of anti-AQP4 antibody at the nadir of exacerbations. A few patients who had short (approx. one to two vertebral segments) spinal cord lesions on MRI were also seropositive with low anti-AQP4 antibody titres, but did have other clinical and MRI features of NMO. Anti-AQP4 antibody titres became lower after high-dose methylprednisolone, and a follow-up showed anti-AQP4 antibody titres remained low in relapse-free periods under immunosuppression. Cerebrospinal fluid (CSF)-anti-AQP4 antibody was detected when the serum-antibody titres exceeded 512x, at the ratio of 1 (CSF) to 500 (serum). Using a sensitive assay, the results of the present study suggest that NMO and high-risk syndrome may be essentially anti-AQP4 antibody-associated disorders, and that the anti-AQP4 antibody titres have significant clinical and immunological implications in NMO.

Key Words: neuromyelitis optica; NMO-IgG; anti-aquaporin-4 antibody; antibody titre; clinical features

Abbreviations: AQP4, aquaporin-4; AZT, azathioprine; CIS, clinically isolated syndrome suggestive of MS; CSF, cerebrospinal fluid; HIMP, high-dose intravenous methylpredonisolone; MS, multiple sclerosis; NMO, neuromyelitis optica; PE, plasma exchange; PSL, prednisolone; VS, vertebral segments

Received January 8, 2007. Revised March 5, 2007. Accepted March 7, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
T. Vincent, P. Saikali, R. Cayrol, A. D. Roth, A. Bar-Or, A. Prat, and J. P. Antel
Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment
J. Immunol., October 15, 2008; 181(8): 5730 - 5737.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
T Takahashi, I Miyazawa, T Misu, R Takano, I Nakashima, K Fujihara, M Tobita, and Y Itoyama
Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations
J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1075 - 1078.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
B Weinstock-Guttman, C Miller, E. Yeh, M Stosic, M Umhauer, N Batra, F Munschauer, R Zivadinov, and M Ramanathan
Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica
Multiple Sclerosis, September 1, 2008; 14(8): 1061 - 1067.
[Abstract] [PDF]


Home page
Arch NeurolHome page
P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al.
Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis
Arch Neurol, July 1, 2008; 65(7): 913 - 919.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al.
Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
Brain, June 1, 2008; 131(6): 1455 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
R. Marignier, J. De Seze, S. Vukusic, F. Durand-Dubief, H. Zephir, P. Vermersch, P. Cabre, G. Cavillon, J. Honnorat, and C. Confavreux
NMO-IgG and Devic's neuromyelitis optica: a French experience
Multiple Sclerosis, May 1, 2008; 14(4): 440 - 445.
[Abstract] [PDF]


Home page
BrainHome page
G. Hudson, C. Mowbray, J. L. Elson, A. Jacob, M. Boggild, A. Torroni, and P. F. Chinnery
Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?
Brain, April 1, 2008; 131(4): e93 - e93.
[Full Text] [PDF]


Home page
Arch NeurolHome page
D. Franciotta, S. Jarius, and F. Aloisi
More on Multiple Sclerosis and Neuromyelitis Optica
Arch Neurol, December 1, 2007; 64(12): 1802 - 1802.
[Full Text] [PDF]


Home page
Arch NeurolHome page
B. Weinshenker, S. Galetta, J. Bennett, D. Kerr, and E. M. Frohman
More on Multiple Sclerosis and Neuromyelitis Optica Reply
Arch Neurol, December 1, 2007; 64(12): 1802 - 1803.
[Full Text] [PDF]


Home page
JWatch NeurologyHome page
Aquaporin-4 Antibodies, Neuromyelitis Optica, and Multiple Sclerosis
Journal Watch Neurology, July 31, 2007; 2007(731): 2 - 2.
[Full Text]


Home page
BrainHome page
A. Compston
Complexity and heterogeneity in demyelinating disease
Brain, May 1, 2007; 130(5): 1178 - 1180.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.